drugset / Trial / NCT05984147
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
NaSequentialOpen-labelTreatment
Summary
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
Timeline
- Start
- 2023-10-19
- Primary completion
- 2027-08-30
- Completion
- 2027-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AUR108 | Unknown | 50 mg | Oral |
| Subject | AUR108 | Unknown | 90 mg | Oral |
| Subject | AUR108 | Unknown | 150 mg | Oral |
| Subject | AUR108 | Unknown | 220 mg | Oral |
| Subject | AUR108 | Unknown | 300 mg | Oral |
Indications
No indication recorded.